Biological roles of the delta family notch ligand Dll4 in tumor and endothelial cells in ovarian cancer

Cancer Research

Volumn 71, Issue 18, 2011, Pages 6030-6039

  Hu, Wei ^a   Lu, Chunhua ^a   Han, Hee Dong ^a   Huang, Jie ^a   Shen, De Yu ^a   Stone, Rebecca L ^a   Nick, Alpa M ^a   Shahzad, Mian M K ^a   Mora, Edna ^a   Jennings, Nicholas B ^a   Lee, Sun Joo ^a   Roh, Ju Won ^a   Matsuo, Koji ^a   Nishimura, Masato ^a   Goodman, Blake W ^a   Jaffe, Robert B ^b   Langley, Robert R ^a   Deavers, Michael T ^a   Lopez Berestein, Gabriel ^a   Coleman, Robert L ^a   Sood, Anil K ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DELTA LIKE LIGAND 4; NOTCH RECEPTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL GROWTH; CONTROLLED STUDY; DISEASE ACTIVITY; DNA METHYLATION; DOWN REGULATION; DRUG RESPONSE; DRUG TARGETING; ENDOTHELIUM CELL; GENE SILENCING; HUMAN; HUMAN TISSUE; HYPOXIA; IMMOBILIZATION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; DOWN-REGULATION; ENDOTHELIAL CELLS; FEMALE; GENE SILENCING; GENE THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE; MICE, NUDE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 80052816881     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2719     Document Type: Article

References (28)

1. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-42. (Pubitemid 26102720)
2. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
3. Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997;80:98-106. (Pubitemid 27270925)
4. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
5. Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007;25:2902-8. (Pubitemid 47123154)
6. Shojaei F, Ferrara N. Antiangiogenic therapy for cancer: an update. Cancer J 2007;13:345-8.
7. Shojaei F, Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Updat 2008;11:219-30.
8. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007;25:911-20. (Pubitemid 47236916)
9. Patel NS, Dobbie MS, Rochester M, Steers G, Poulsom R, Le Monnier K, et al. Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res 2006;12:4836-44. (Pubitemid 44338568)
10. Sainson RC, Harris AL. Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med 2007;13:389-95.
11. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444:1032-7. (Pubitemid 46018516)
12. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 2007;67:11244-53. (Pubitemid 350248550)
13. Lin YG, Han L, Merritt W, Landen CN, Deavers MT, et al. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 2007;109:332-40. (Pubitemid 46106248)
14. Halder J, Landen CN Jr, Lutgendorf SK, Li Y, Jennings NB, Fan D, et al. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res 2005;11:8829-36. (Pubitemid 43005935)
15. Langley RR, Ramirez KM, Tsan RZ, Van Arsdall M, Nilsson MB, Fidler IJ. Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res 2003;63:2971-6. (Pubitemid 36667171)
16. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010;18:185-97.
17. Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, et al. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol 2004;165:1087-95. (Pubitemid 39297716)
18. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006;12:939-44. (Pubitemid 44175146)
19. Schadler KL, Zweidler-McKay PA, Guan H, Kleinerman ES. Delta-like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing's sarcoma. Clin Cancer Res 2010;16:848-56.
20. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49. (Pubitemid 351656458)
21. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
22. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, et al. PDGFC mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009;15:21-34.
23. Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, et al. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res 2011;17:372-81.
24. Li JL, Harris AL. Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front Biosci 2009;14:3094-110.
25. Thurston G, Kitajewski J. VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis. Br J Cancer 2008;99:1204-9.
26. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinomaCancer Res 2007;67:1757-68.
27. Holderfield MT, Hughes CC. Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis. Circ Res 2008;102:637-52. (Pubitemid 351457853)
28. Shi W, Harris AL. Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials. J Mammary Gland Biol Neoplasia 2006;11:41-52. (Pubitemid 44309188)